Zimmer Biomet (NYSE:ZBH) Announces Earnings Results

Zimmer Biomet (NYSE:ZBH) announced its quarterly earnings data on Tuesday. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23, FiscalAI reports. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 EPS. Zimmer Biomet updated its FY 2026 guidance to 8.400-8.550 EPS.

Here are the key takeaways from Zimmer Biomet’s conference call:

• Raised full‑year targets — management increased adjusted EPS guidance to $8.40–$8.55 and now expects free cash flow growth of 9%–11%, citing strong Q1 cash generation and execution.
• Top‑line and tech momentum — Q1 net sales were $2.087B (organic constant‑currency +2.9%), with technology/data, bone cement and surgical businesses up ~12% and robotics/technology sales growing at very strong double‑digit rates (~30%).
• U.S. go‑to‑market transition is progressing — the shift to dedicated/specialized reps has driven rapid productivity gains in transitioned territories but caused modest short‑term disruption; the company expects to complete the transformation by end‑2027.
• Monogram (mBôs) progress — enrollment in the 102‑patient clinical study is complete, management expects U.S. semiautonomous approval and launch in early 2027 (fully autonomous later), and plans to hire >200 robotic clinical sales reps to support commercialization.
• Q1 results included a roughly $0.20 per‑share tariff benefit from IEEPA invalidation that partially pulled forward margin improvement, and management still forecasts 2026 operating margins down slightly (under ~50 bps) versus 2025.

Zimmer Biomet Price Performance

Shares of ZBH traded up $1.82 during midday trading on Thursday, reaching $81.89. The stock had a trading volume of 978,392 shares, compared to its average volume of 2,279,938. Zimmer Biomet has a 52 week low of $79.83 and a 52 week high of $108.29. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The company has a market capitalization of $15.85 billion, a P/E ratio of 23.15, a P/E/G ratio of 1.89 and a beta of 0.61. The firm’s 50 day moving average price is $92.87 and its 200-day moving average price is $92.81.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.2%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds have recently added to or reduced their stakes in the company. DV Equities LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $25,000. Gen Wealth Partners Inc bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $31,000. Headlands Technologies LLC bought a new stake in Zimmer Biomet during the second quarter worth approximately $37,000. EFG International AG bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $55,000. Finally, Mpwm Advisory Solutions LLC bought a new stake in Zimmer Biomet during the third quarter worth approximately $65,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 beat and raised guidance — Zimmer Biomet reported Q1 EPS of $2.09 (vs. $1.86 est.) and revenue of about $2.09B, with revenue up ~9% year/year and the firm raising FY 2026 EPS guidance to roughly $8.40–8.55. This underpins the company’s underlying operational strength. Earnings Call Highlights
• Neutral Sentiment: Full call/transcript and coverage — The earnings call and full transcripts are available (useful for details on segment performance and margin drivers). Market commentary notes the beats but some premarket/early weakness after results. Earnings Call Transcript
• Neutral Sentiment: Stock “buzz” and peer performance — Data vendors flagged rising buzz across NYSE composites but MarketWatch noted ZBH underperformed peers on the day; these are informational signals rather than direct fundamentals. Buzz Grows Across NYSE Composite Trend
• Negative Sentiment: Finance chief resignation — A senior finance executive departure prompted a large intraday decline and headlines describing a plunge to a multi‑year low, creating near‑term uncertainty around financial leadership and execution. Plunges to 13-Year Low on Finance Chief Resignation
• Negative Sentiment: Analyst price‑target cuts and rating shifts — Multiple firms trimmed targets or issued neutral/equal‑weight opinions (JPMorgan to $95/neutral; Wells Fargo to $90/equal weight; Truist trimmed target to $92 while keeping hold). The cluster of cuts is weighing on sentiment and likely amplifying the sell‑off. Analyst Actions (Benzinga)

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price on the stock. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Sunday, April 19th. Finally, Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $102.43.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.